Q&A: Forbion Capital Partners' Sander Slootweg
Life-sciences-focused venture firm Forbion Capital Partners recently held a €360m final close for its fourth flagship fund, surpassing its initial hard-cap of €350m. Managing partner Sander Slootweg speaks to Francesca Veronesi about the fundraising process, the firm's 'build' strategy and the European life sciences venture market
More on Benelux
MML launches lower-mid-market strategy for UK, Northern European B2B assets
London-headquartered GP invested in AI provider MIcompany in first deal for new strategy this week
Integra Partners heads for year-end close for EUR 250m second fund
Vehicle is open to retail investors with tickets of EUR 500,000-plus and will make fund and co-investments
GP Profile: Armen eyes “new frontier” for GP stakes in Europe
France-headquartered GP stakes investor is seeking to support sponsors as they become multi-strategy managers, co-founder Dominique Gaillard tells Unquote
IPEM 2023: GPs battle fundraising blues on the Côte d'Azur
Sponsors remain broadly optimistic despite fundraise bottlenecks and a growing number of LPs faced with tough choices on manager selection
Latest News
CVC acquires Scan Global logistics from AEA Investors
AEA and management have reinvested for a minority stake in the Danish logistics provider
Eurazeo shakes up executive board; CEO Virginie Morgon to depart
New board members are chairmen Christophe Bavière and William Kadouch-Chassaing, as well as Sophie Flak and Olivier Millet
Seventure preps third generation of microbiome fund
Health for Life III to be slightly larger than EUR 250m predecessor; will invest in Europe, US, Israel
Idacapital targets close to USD 30m for impact fund
Turkish VC seeks to raise USD 5m every six months for new rolling investment vehicle